EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept

Hermine I Brunner iD, Nikolay Tzaribachev, Ingrid Louw, Inmaculada Calvo Penades, Francisco Avila-Zapata, Gerd Horneff, Ivan Foeldvari iD, Daniel J Kingsbury, Maria Eliana Paz Gastanaga, Carine Wouters, Johannes Breedt, Robert Wong und 6 weitere

Arthritis Care & Research · 2023

DOI: 10.1002/acr.25156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis Care & Research, 2023. Verfasst von Hermine I Brunner und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Antirheumatic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: BMSF.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To investigate the frequency and trajectories of individual patients with polyarticular‐course juvenile idiopathic arthritis (JIA) achieving novel composite end points on abatacept.

Methods

Data from a clinical trial of subcutaneous abatacept (NCT01844518) and a post hoc analysis of intravenous abatacept (NCT00095173) in patients with polyarticular‐course JIA were included. Three end points were defined and evaluated: combined occurrence of low disease activity (LDA) measured by the Juvenile Arthritis Disease Activity Score; 50% improvement in American College of Rheumatology criteria for JIA (ACR50); and patient‐reported outcomes. Patient‐reported outcomes included visual analog scale score of minimal pain (pain‐min) and Childhood Health Assessment Questionnaire disability index score of 0 (C‐HAQ DI0). In this post hoc analysis, maintenance of month 13 and 21 end points (LDA+pain‐min, LDA+C‐HAQ DI0, and ACR50+pain‐min) in those who achieved them at month 4 was determined.

Results

Composite end points (LDA+pain‐min, LDA+C‐HAQ DI0, and ACR50+pain‐min) were achieved at month 4 (44.7%, 19.6%, and 58.9% of the 219 patients treated with subcutaneous abatacept, respectively). Of those who achieved LDA+pain‐min at month 4, 84.7% (83 of 98) and 65.3% (64 of 98) maintained LDA+pain‐min at months 13 and 21, respectively. The proportions of patients meeting LDA+pain‐min outcomes increased from 44.7% (98 of 219) at month 4 to 54.8% (120 of 219) at month 21. The frequency of patients who met an LDA+C‐HAQ DI score of 0 increased from 19.6% (43 of 219) at month 4 to 28.8% (63 of 219) at month 21.

Conclusion

Among individual patients with polyarticular‐course JIA treated with abatacept who achieved 1 of the combined clinical and patient‐reported outcomes composite end points, many maintained them over 21 months of abatacept treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileAntirheumatic AgentsHumansChildAbataceptTreatment OutcomePain

Substanzen

AbataceptAntirheumatic Agents

Autor:innen und Institutionen

  • Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • PRI Research, Bad Bramstedt, Germany.
  • Panorama Medical Centre, Cape Town, South Africa.
  • Hospital Universitario y Politécnico de La Fe, Valencia, Spain.
  • Hospital Star Medica Merida, Yucatan, Mexico.
  • Asklepios Klinik, Sankt Augustin, Germany, and University of Cologne, Cologne, Germany.

ORCID-Profile: Hermine I Brunner, Ivan Foeldvari, Daniel J Lovell, Nicolino Ruperto

Förderung

  • BMSF

Zitieren

APA

Brunner, H. I., Tzaribachev, N., Louw, I., Calvo Penades, I., Avila-Zapata, F., Horneff, G., Foeldvari, I., Kingsbury, D. J., Paz Gastanaga, M. E., Wouters, C., Breedt, J., Wong, R., Askelson, M., Zhuo, J., Martini, A., Lovell, D. J., Ruperto, N., & Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) investigators (2023). Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care & Research. https://doi.org/10.1002/acr.25156

Vancouver

Brunner HI, Tzaribachev N, Louw I, Calvo Penades I, Avila-Zapata F, Horneff G, et al. Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept. Arthritis Care & Research. 2023. doi:10.1002/acr.25156

BibTeX
@article{Brunner2023,
  author = {Brunner, Hermine I and Tzaribachev, Nikolay and Louw, Ingrid and Calvo Penades, Inmaculada and Avila-Zapata, Francisco and Horneff, Gerd and Foeldvari, Ivan and Kingsbury, Daniel J and Paz Gastanaga, Maria Eliana and Wouters, Carine and Breedt, Johannes and Wong, Robert and Askelson, Margarita and Zhuo, Joe and Martini, Alberto and Lovell, Daniel J and Ruperto, Nicolino and Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) investigators, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG) investigators},
  title = {Long‐Term Maintenance of Clinical Responses by Individual Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis Treated With Abatacept},
  journal = {Arthritis Care & Research},
  year = {2023},
  doi = {10.1002/acr.25156}
}
Kostenlos starten →